In a mouse model on rejection of an allogeneic subcutaneous tumor as created by Hammond-McKribben et al. [22], another mTOR inhibitor, the rapamycin derivate SDZ RAD, was used to prevent rejection of allogeneic tumors.
This imaging technique could equally be used in imaging a model of chronic rejection, and as with acute rejection, the current view is that macrophages promote worse graft outcome through the release of inflammatory mediators and regulation of the cytokine dynamics [38].
Our results indicate that down-regulation of the indirect alloresponse by donor apoptotic cell therapy prevents/ameliorates CAV in aortic allografts, an established model of chronic rejection elicited through the indirect pathway.
Here we use a model of tumour rejection involving a melanoma cell line expressing Fas ligand (B16FasL) to study the effect of Treg on both innate and adaptive immune responses.
In murine models of graft rejection [12] and graft-versus-host disease [15], we found that adoptive transfer of Th2 cells that were manufactured ex vivo in rapamycin ("Th2.R cells") were more effective than control Th2 cells; the increased in vivo efficacy of Th2.R cells is likely due to their rapamycin-induced anti-apoptotic phenotype, which permits prolonged in vivo T cell persistence [13].
Orally administered FTY720 is effective in a number of preclinical models of transplant rejection and autoimmune disease.
Multiple studies have demonstrated that anti-CD11/CD18 anti-CD11/CD18 antibodies with reduced inflareassociatedinjury in models of allograft rejection, endotoxin challenge, hemorrhagic shock, aspiration pneumonia, bacterial pneumonia, and ischemia/reperfusion, among others [ 34].
Accordingly, we expect that it will soon be possible to provide additional evidence that could lead to one of a range of outcomes, including support for the model, revision of the model, or rejection of the model.
In concordant models, this type of rejection is prevented by brief complement inhibition by cobra venom factor (CVF) and sustained T-cell immunosuppression by cyclosporin A (CyA).
